This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/514667-pfizer-india-vaccine-application/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Pfizer withdraws application for Covid-19 vaccine emergency use in India after regulator requests more data | Pfizer withdraws application for Covid-19 vaccine emergency use in India after regulator requests more data |
| (7 months later) | |
| Pfizer says it has withdrawn a request to have its Covid-19 vaccine authorized for use in India. The company has promised to resubmit the application once it gathers more data. | Pfizer says it has withdrawn a request to have its Covid-19 vaccine authorized for use in India. The company has promised to resubmit the application once it gathers more data. |
| The US-based drug-maker said that the decision was taken after a meeting with an expert panel from India’s state regulator on Wednesday. | The US-based drug-maker said that the decision was taken after a meeting with an expert panel from India’s state regulator on Wednesday. |
| “Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time,” Pfizer’s spokesperson said in a statement. | “Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time,” Pfizer’s spokesperson said in a statement. |
| The company added that it will “resubmit its approval request with additional information as it becomes available in the near future.” | The company added that it will “resubmit its approval request with additional information as it becomes available in the near future.” |
| The Economic Times newspaper cited a government source saying that Pfizer wanted a clinical trial waiver for its vaccine, developed jointly with the German firm BioNTech, but the regulator has insisted on a bridging study in India. The experts wanted to see how the vaccine would work among the Indian population before it could be cleared for general use in the country, the source explained. | The Economic Times newspaper cited a government source saying that Pfizer wanted a clinical trial waiver for its vaccine, developed jointly with the German firm BioNTech, but the regulator has insisted on a bridging study in India. The experts wanted to see how the vaccine would work among the Indian population before it could be cleared for general use in the country, the source explained. |
| Vinod K. Paul, the head of a government panel on vaccine strategy, told Reuters earlier this month a bridging trial in India is a “precondition” for any vaccine to be allowed in the country. | Vinod K. Paul, the head of a government panel on vaccine strategy, told Reuters earlier this month a bridging trial in India is a “precondition” for any vaccine to be allowed in the country. |
| India launched a nationwide immunization campaign on January 16, using a locally manufactured version of the AstraZeneca-Oxford vaccine and a vaccine called Covaxin, made by an Indian pharmaceutical company, Bharat Biotech. | India launched a nationwide immunization campaign on January 16, using a locally manufactured version of the AstraZeneca-Oxford vaccine and a vaccine called Covaxin, made by an Indian pharmaceutical company, Bharat Biotech. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |